{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:47:29Z","timestamp":1780602449105,"version":"3.54.1"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,9,28]],"date-time":"2006-09-28T00:00:00Z","timestamp":1159401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2006,12]]},"abstract":"Abstract<\/jats:title>\n \n Diagnosis of the myeloproliferative disorders, polycythemia vera (PV), essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF) is difficult due to lack of diagnostic markers. Recently, the acquisition of a mutation in the Janus kinase 2 (\n JAK2<\/jats:italic>\n ) gene by hemopoietic cells has been described as a genetic defect underlying myeloproliferative disorders. The mutation leads to constitutive activation of JAK2, a tyrosine kinase involved in cytokine receptor signalling. Because of the clinical importance of this mutation (\n JAK2<\/jats:italic>\n V617F) in diagnosing myeloproliferative disorders and its relevance for disease progression, we developed a semi\u2010quantitative real\u2010time PCR test to detect\n JAK2<\/jats:italic>\n V617F. With this assay, quantities down to 0.8%\n JAK2<\/jats:italic>\n V617F amongst wild\u2010type DNA could reliably be detected. For quantification purposes, low intra\u2010 and inter\u2010assay variabilities ensure good reproducibility of the assay. Thus the\n JAK2<\/jats:italic>\n V617F qPCR assay described here is quick, robust, simple and more sensitive than direct sequencing, RFLP, ARMS assay and other methods published so far to detect\n JAK2<\/jats:italic>\n V617F. We therefore believe that the assay will contribute to early diagnosis of myeloproliferative disorders and to disease management, especially when JAK2\u2010specific inhibitors have become available for therapeutic use. Copyright \u00a9 2006 John Wiley & Sons, Ltd.\n <\/jats:p>","DOI":"10.1002\/hon.800","type":"journal-article","created":{"date-parts":[[2006,9,28]],"date-time":"2006-09-28T06:01:43Z","timestamp":1159423303000},"page":"227-233","source":"Crossref","is-referenced-by-count":31,"title":["A sensitive and reliable semi\u2010quantitative real\u2010time PCR assay to detect\n JAK2<\/i>\n V617F in blood"],"prefix":"10.1002","volume":"24","author":[{"given":"J","family":"Poodt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Fijnheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"IBB","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MHA","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,9,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.02.011"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.1.128"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1183"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05776.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05682.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1320"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404069"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2899"},{"key":"e_1_2_1_16_2","volume-title":"Myelodysplastic syndromes: Introduction","author":"Brunning RD","year":"2001"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03669"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00789-5"},{"key":"e_1_2_1_19_2","first-page":"253","article-title":"Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders","volume":"125","author":"Campbell PJ","year":"2006","journal-title":"Methods Mol Med"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.800","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:46:25Z","timestamp":1700009185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9,28]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1002\/hon.800"],"URL":"https:\/\/doi.org\/10.1002\/hon.800","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1046621.496615","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9,28]]}}}